pharmaphorum
MARCH 11, 2021
The therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. If VX-880 works, it could remove or reduce the reliance of patients with the disease on insulin injections. That implantable technology was at the heart of the Semma acquisition.
XTalks
SEPTEMBER 15, 2020
In addition to the vaccine, the company is also developing an investigational drug called Remygen for the regeneration of endogenous insulin production and to improve hormonal response to hypoglycemia; trials to test the treatment are currently ongoing in patients that have been living with type 1 diabetes for more than five years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
NOVEMBER 22, 2022
Type 1 diabetes, also known as insulin-dependent or juvenile diabetes, is an autoimmune disease that occurs when the body is unable to make enough insulin due to destruction of the beta insulin-producing cells in the pancreas. In the US, it is estimated that 1.45 million people are currently living with type 1 diabetes.
Scienmag
MAY 4, 2021
Credit: Lin-Feng Chen A new study, published in JCI Insight, looks at how Brd4, a regulator of the innate immune response, influences diet-induced obesity. The researchers believe that Brd4 could be used as a target for obesity and insulin resistance. Approximately one-third of the adults and one in five children in the U.S.
pharmaphorum
JULY 11, 2022
Vertex’ therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The first patient treated with the therapy saw their need for insulin reduce to almost zero, helping VX-880 claim a fast-track designation from the FDA.
XTalks
SEPTEMBER 17, 2020
Acromegaly Surrogate Endpoint: Serum growth hormone and serum insulin-like growth factor 1 (IGF-1) are acceptable surrogate endpoints for acromegaly clinical trials involving somatostatin analogs such as octreotide, lanreotide and pasireotide. Also known as Berardinelli-Seip syndrome, there are four subtypes of lipodystrophy.
The Pharma Data
DECEMBER 15, 2020
The company will use its Tepezza (teprotumumab-trbw), an insulin-like growth factor type-1 receptor inhibitor that’s already approved for treating thyroid eye disease. CUE-300 Series Immuno-STATs may offer autoimmune patients therapeutic benefits without compromising their immune systems.
Expert insights. Personalized for you.
98 
Let's personalize your content